Free Trial

Lipocine (LPCN) Competitors

Lipocine logo
$3.15 -0.08 (-2.48%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$3.16 +0.00 (+0.16%)
As of 08/1/2025 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LPCN vs. PMVP, QNTM, AVTX, BRNS, MNOV, CELU, ASRT, INCR, IRD, and GNTA

Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include PMV Pharmaceuticals (PMVP), Quantum Biopharma (QNTM), Avalo Therapeutics (AVTX), Barinthus Biotherapeutics (BRNS), MediciNova (MNOV), Celularity (CELU), Assertio (ASRT), InterCure (INCR), Opus Genetics (IRD), and Genenta Science (GNTA). These companies are all part of the "pharmaceutical products" industry.

Lipocine vs. Its Competitors

PMV Pharmaceuticals (NASDAQ:PMVP) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

In the previous week, PMV Pharmaceuticals' average media sentiment score of 1.70 beat Lipocine's score of 0.00 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
PMV Pharmaceuticals Very Positive
Lipocine Neutral

PMV Pharmaceuticals has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.

Lipocine has higher revenue and earnings than PMV Pharmaceuticals. Lipocine is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PMV PharmaceuticalsN/AN/A-$58.71M-$1.18-1.19
Lipocine$11.20M1.50$10K-$1.02-3.09

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Comparatively, 6.4% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

PMV Pharmaceuticals presently has a consensus price target of $5.50, suggesting a potential upside of 292.86%. Lipocine has a consensus price target of $9.00, suggesting a potential upside of 185.71%. Given PMV Pharmaceuticals' higher possible upside, equities analysts plainly believe PMV Pharmaceuticals is more favorable than Lipocine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PMV Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Lipocine
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Lipocine's return on equity of -26.68% beat PMV Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
PMV PharmaceuticalsN/A -32.54% -29.59%
Lipocine N/A -26.68%-24.77%

Summary

PMV Pharmaceuticals beats Lipocine on 6 of the 11 factors compared between the two stocks.

Get Lipocine News Delivered to You Automatically

Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LPCN vs. The Competition

MetricLipocineMED IndustryMedical SectorNASDAQ Exchange
Market Cap$17.28M$2.46B$5.48B$9.51B
Dividend YieldN/A1.81%4.73%4.08%
P/E Ratio-3.098.9728.6723.80
Price / Sales1.50437.63373.9066.65
Price / CashN/A157.7635.4557.96
Price / Book0.804.838.275.55
Net Income$10K$31.62M$3.24B$259.03M
7 Day Performance-8.43%-5.28%-3.69%-4.59%
1 Month Performance1.29%4.38%4.33%4.46%
1 Year Performance-36.49%-2.49%25.95%18.03%

Lipocine Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LPCN
Lipocine
2.6175 of 5 stars
$3.15
-2.5%
$9.00
+185.7%
-38.0%$17.28M$11.20M-3.0910Upcoming Earnings
PMVP
PMV Pharmaceuticals
3.5341 of 5 stars
$1.51
+7.1%
$5.50
+264.2%
-11.9%$73.25MN/A-1.2850Positive News
Upcoming Earnings
Gap Down
QNTM
Quantum Biopharma
N/A$24.88
-1.1%
N/AN/A$73.12MN/A-1.56N/AGap Down
AVTX
Avalo Therapeutics
3.058 of 5 stars
$6.58
-1.6%
$30.00
+355.9%
-28.6%$72.44M$440K0.0040News Coverage
Gap Down
BRNS
Barinthus Biotherapeutics
2.2707 of 5 stars
$1.55
-13.4%
$6.25
+303.2%
-7.1%$72.21M$14.97M-0.95107Upcoming Earnings
Gap Down
MNOV
MediciNova
2.678 of 5 stars
$1.45
-0.7%
$7.00
+382.8%
+8.3%$71.61M$1M-6.3010News Coverage
Upcoming Earnings
Gap Up
High Trading Volume
CELU
Celularity
0.2428 of 5 stars
$3.29
+11.1%
N/A-1.0%$70.89M$54.22M-1.24220News Coverage
Analyst Upgrade
Gap Up
ASRT
Assertio
1.7166 of 5 stars
$0.73
-2.0%
$2.63
+262.1%
-48.4%$70.88M$124.96M-2.2720News Coverage
Upcoming Earnings
INCR
InterCure
N/A$1.51
-2.6%
N/A-32.1%$70.64M$66.28M0.00350Gap Up
IRD
Opus Genetics
1.1812 of 5 stars
$1.20
+1.7%
$7.33
+511.1%
N/A$70.40M$10.99M-0.5714
GNTA
Genenta Science
1.6585 of 5 stars
$3.75
-0.8%
$25.00
+566.5%
-13.5%$69.14MN/A0.007Positive News
Short Interest ↑

Related Companies and Tools


This page (NASDAQ:LPCN) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners